ReviewAntibiotics (Basel, Switzerland)2021
Ever-Adapting RND Efflux Pumps in Gram-Negative Multidrug-Resistant Pathogens: A Race against Time.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Insights into Haemophilus macrolide resistance: A comprehensive systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Article
- Spider Venom Peptides as Potential Allosteric Inhibitors of Undecaprenyl Diphosphatase (UppP) fromToxins · 2026Article
- AcrAB-NodT overexpression drives envelope destabilization and metal sensitivity in Caulobacter vibrioides.Archives of microbiology · 2026Review
- Article
- Co-development of efflux pump inhibitors with antibiotics on targeting structural and mutational aspects of AcrB subunit.Molecular diversity · 2026Article
- Cloning and Characterizing Multidrug Efflux Pumps.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Labeling of Specific Residues of the Multidrug Transporter AcrB with Its Fluorescent Substrate.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Molecular Insights into the MdtABC Efflux Pump Genes in ClinicalCurrent pharmaceutical design · 2026Article
- Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- Beyond antibiotic resistance: evidence for resistance-nodulation-division (RND) efflux pumps as virulence determinants.Microbiology and molecular biology reviews : MMBR · 2025Review
- EefR mutations drive sanguinarine resistance by activating cryptic multidrug efflux pumps in AcrB-NullVirulence · 2025Article
- Computational Evaluation of Fusarium nygamai Compounds as AcrD Efflux Pump Protein Inhibitors of Salmonella Typhimurium.Molecular biotechnology · 2025Article
- Review
- Functional interplay between RND efflux pumps and GacS inApplied and environmental microbiology · 2025Article
- Evaluating the Link between Efflux Pump Expression and Motility Phenotypes inACS infectious diseases · 2025Article
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- Zinc sulfate acts as an efflux pump inhibitor on Pseudomonas aeruginosa clinical isolates.World journal of microbiology & biotechnology · 2025Article
- Genomic features, antimicrobial resistance and pathogenicity assessment of Escherichia coli serotype O177:H51 strain JS01 isolated from a diseased chicken.BMC microbiology · 2025Article
- Resistance ofAntibiotics (Basel, Switzerland) · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The rise in multidrug resistance (MDR) is one of the greatest threats to human health worldwide. MDR in bacterial pathogens is a major challenge in healthcare, as bacterial infections are becoming untreatable by commercially available antibiotics. One of the main causes of MDR is the over-expression of intrinsic and acquired multidrug efflux pumps, belonging to the resistance-nodulation-division (RND) superfamily, which can efflux a wide range of structurally different antibiotics. Besides over-expression, however, recent amino acid substitutions within the pumps themselves-causing an increased drug efflux efficiency-are causing additional worry. In this review, we take a closer look at clinically, environmentally and laboratory-evolved Gram-negative bacterial strains and their decreased drug sensitivity as a result of mutations directly in the RND-type pumps themselves (from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.